Arrow Brand Expansion May Boost Teleflex

Zacks

The recent product launch by Teleflex Incorporated (TFX) should further boost the positive trend displayed by TFX’s stock price over the last week. Moreover, 1 out of 6 estimates for 2014 moved up in the last 7 days. On a year-to-date basis, the company has returned an impressive 14% to its investors.

In an effort to expand its Arrow brand of products, Teleflex launched two new Arrow Vascular Access products – Arrow VPS G4 Device and the Arrow JACC (Jugular Axillo-subclavian Central Catheter) with Chlorag+ard Technology – at the annual Vascular Access conference.

What is Arrow VPS G4 Device?

The Arrow VPS G4 Device is the latest innovation which uses cutting-edge technology for accurate CVC (Central Venous Catheter) and PICC (peripherally inserted central catheters) tip positioning. The device is used as an alternative option to fluoroscopy or chest X-ray for CVC tip placement in adults. Some of the additional features include easy-to-follow symbols, statement of final catheter position and Wi-Fi access to simplify the entire procedure of therapy.

What is Arrow JACC with Chlorag+ard Technology?

The Arrow JACC with Chlorag+ard Technology is a pioneering antimicrobial and antithrombogenic catheter intended for both acute and long-term use. The device, specifically designed to support CVC placement by Vascular Access Specialists, received U.S. Food and Drug Administration (:FDA) approval in Nov 2012. The Chlorag+ard Technology installed on the device has the ability to provide protection against thrombosis and infection for up to 1 month.

Roughly, 250,000 patients in the U.S. acquire catheter-related bloodstream infections every year, and according to the Center for Disease Control and Prevention (:CDC), an estimated 30,000 to 62,000 patients die annually from such infections. The Arrow JACC with its unique technology reinforces Teleflex’ commitment toward eradicating procedural complications in the field of vascular care.

Along with the products-launch, Teleflex sponsored two symposia during the conference. The first, “Breaking Through: A Guide to Placing CVCs,” highlighted CVC placements via the Vascular Access Specialist, along with a Platinum Showcase focusing on insertion site alternatives: “When the Arm Is No Longer an Option.”

The second symposium, featuring two presentations: “New Advances in Arrow Vascular Positioning Technology” and “Comparative Data Using PICC Placement Technology – 800 Clinical Cases” demonstrated recent developments in tip positioning technology.

TFX is a global leader in supply of medical devices used in critical care and surgery. The company focuses on profitable and consistent growth and expects its sales growth to surpass market growth in the long run. It also plans to gain market share in key product areas in the near term.

However, the company operates in a highly competitive medical devices-industry and also has to confront a stringent regulatory environment. The demand for its products is susceptible to healthcare reimbursement systems in the domestic as well as the international market.

Teleflex has a Zacks Rank #3 (Hold). While we remain on the sidelines regarding this company, medical instruments stocks that are worth considering include Luminex (LMNX), Given Imaging (GIVN) and Echo Therapeutics (ECTE). All these stocks carry a Zacks Rank #2 (Buy).

Read the Full Research Report on TFXRead the Full Research Report on LMNXRead the Full Research Report on GIVNRead the Full Research Report on ECTEZacks Investment Research
View Comments (0)